Welcome to GBCC

Gradiant Bioconvergence (GBCC) is a global partner
in new drug development.

GBCC owns Asia's largest cancer patient-derived organoid (PDO) banking, drug efficacy
and safety evaluation platform using PDOs, AI-based new drug target discovery platform,
and central nervous system disease modeling platform of iPSC-derived organoids.
We support first-in-class innovation in all new drug modalities.

Gradiant Bioconvergence CEO Jinguen Rheey

Major career background

  • Ph.D @ L'Ecole Normale Supérieure (France)
  • M.S @ The George Washington University (USA)
  • B.S @ Pohang University of Science and Technology (POSTECH)
  • Seoul Science High School (International Biology Olympiad bronze medal)

Main educational background

2022.04 ~ Present
CEO of Gradiant Bioconvergence Co., Ltd.
Gradiant Co., Ltd. Managing Director (Head of Bio Working Group)
2020.06 ~ 2022.03
Interpark Bioconvergence Co., Ltd.
2019.04 ~ 2020.05
Hugel Co., Ltd.
2016.08 ~ 2019.03
Donga ST Co., Ltd.
2011.07 ~ 2016.07
Samsung Electronics Co., Ltd.